Trends in Inflammatory Bowel Disease Therapy 1999: The proceedings of a symposium organized by AXCAN PHARMA, held in Vancouver, BC, August 27–29, 1999 PDF
Preview Trends in Inflammatory Bowel Disease Therapy 1999: The proceedings of a symposium organized by AXCAN PHARMA, held in Vancouver, BC, August 27–29, 1999
Trends in Inflammatory Bowel Disease Therapy 1999 Trends in Inflammatory Bowel Disease Therapy 1999 Edited by C.N. Williams Oivision of Gastroenter%gy Oepartment of Medicine Oa/housie University Halifax Nova Scotia, Canada R.F. Bursey R.S. Mcleod Memoria/ University of Newfound/and University of Toronto Facu/ty of Medicine Mount Sinai Hospita/ The Health Sciences Centre Toronto St John's Ontario, Canada Newfound/and, Canada O.G. Gall loR. Sutherland Facu/ty of Medicine Facu/ty of Medicine The University of Ca/gary The University of Ca/gary A/berta, Canada A/berta, Canada F. Martin J.lo Wallace University of Montrea/ Faculty of Medicine Canada The University of Ca/gary A/berta, Canada The proceedings of a symposium organized by AXCAN PHARMA, he/d in Vancouver, ac, August 27-29, 1999 • ~. ,. SPRINGER SCIENCE+BUSINESS MEDIA, BV A CLP. Catalogue record for this book is available from the Library of Congress ISBN 978-94-010-5769-1 ISBN 978-94-011-4002-7 (eBook) DOI 10.1007/978-94-011-4002-7 Printed on acid-free pap er Ali rights reserved © 2000 Springer Science+Business Media Dordrecht Originally published by Kluwer Academic Publishers and Axcan Pharma in 2000 Softcover reprint ofthe hardcover lst edition 2000 No part of the material protected by this copyright notice may be reproduced or utilized in any form or by any means, electronic or mechanical, inc1uding photocopying, recording or by any information storage and retrieval system, without prior permission from the copyright owners. Contents List of Principal Authors viii Preface xv CN Williams Section I: GENETICS 1 Genetics of inflammatory bowel disease: where are we? MS Silverberg, A-K Somani and KA Siminovitch 3 2 Genetics of inflammatory bowel disease: why is it important? OPJewell 13 3 Genetics of IBD: impact on immune function C Fiocchi 23 Section II: PATHOGENESIS 4 Bacterial factors in inflammatory bowel disease pathogenesis WFOoe 39 5 Inflammatory bowel disease: autoimmunity or chronic inflammation? L Mayer 46 6 Neutrophil-epithelial interactions, and efforts to down-regulate them, in inflammatory bowel disease AT Gewirtz and JL Madara 54 7 Understanding inflammatory bowel disease at the millennium: tentative answers and future questions OK Podolsky 61 v CONTENTS Section III: CLINICAL CHALLENGES IN INFLAMMATORY BOWEL DISEASE 8 Diagnosis of inflammatory bowel disease: an update M Robinson 73 9 Recent developments in the diagnosis and management of paediatric inflammatory bowel disease EG Seidman, M Dubinsky, H Patriquin, G Marx and Y Theoret 87 10 Inflammatory bowel disease in the elderly GR Greenberg and I Tai 96 Section IV: CURRENT THERAPY IN INFLAMMATORY BOWEL DISEASE 11 Induction of remission in ulcerative colitis SB Hanauer 107 12 Remission maintenance in ulcerative colitis J SchOlmerich 117 13 Induction therapy for Crohn's disease AH Steinhart 128 14 Maintenance of remission in Crohn's disease P Rutgeerts 137 Section V: BONE DISEASE IN INFLAMMATORY BOWEL DISEASE 15 Risk factors and prevalence of bone disease in inflammatory bowel disease CN Bernstein 147 16 Management of low bone mass in patients with inflammatory bowel disease A Tenenhouse 163 17 Steroid-induced osteonecrosis in inflammatory bowel disease: Canadian legal status RM Carter and MGA Grace 173 vi CONTENTS Section VI: ALTERNATIVE THERAPY 18 Psychotherapy for inflammatory bowel disease: new prospects RG Maunder 185 19 The use of complementary and alternative medicine by patients with inflammatory bowel disease RJ Hi/sden and MJ Verhoef 194 20 Gut inflammation: is there a role for herbal medicines? MJS Miller 201 21 The role of nutrition in the treatment of inflammatory bowel disease MA Gassul/ 207 Section VII: NEW THERAPEUTIC APPROACHES 22 Antibodies to proinflammatory cytokines LC Karp and SR Targan 219 23 Immunomodulation of Crohn's disease C van Montfrans, T ten Hove and SJH van Deventer 227 24 Application of recombinant DNA technology to the identification of novel therapeutic targets in inflammatory bowel disease GE Wild, J Hasan, MJ Rope/eski, KA Waschke, C Cossette, L Dufresne, BOH Le and ABR Thomson 234 25 The use of probiotics in inflammatory bowel disease M Campieri, P Gionchetti, F Rizzel/o and A Venturi 252 Index 259 vii List of Principal Authors C. N. BERNSTEIN University of Manitoba Section of Gastroenterology GB-443 Health Sciences Centre 820 Sherbrook Street Winnipeg MB R3A-1 R9 Canada R. F. BURSEY Department of Medicine "Gastroenterology" Memorial University of Newfoundland Faculty of Medicine The Health Sciences Centre St. John's, NFLD A1B 3B6 Canada M. CAMPIERI Policlinico S. Orsola Department of Internal Medicine & Gastroenterology University of Bologna Policlinico Sant'Orsola-Malpighi via Massarenti, 9 40138 Bologna Italy R.M.CARTER Bennett Jones Barristers and Solicitors 1000, 10035-105 Street Edmonton AB T5J 3T2 Canada viii LIST OF PRINCIPAL CONTRIBUTORS W. F. DOE University of Birmingham Medicine, Dentistry & Health Sciences The Medical School Edgbaston Birmingham B152TT UK C. FIOCCHI Division of Gastroenterology University Hospitals of Cleveland and Case Western Reserve School of Medicine (BRB) 10900 Euclid Avenue Cleveland, OH 44106-4952 USA D.G.GALL Faculty of Medicine The University of Calgary 3330 Hospital Dr. NW Calgary, AB T2N 4N1 Canada M.A.GASSULL Department of Gastroenterology Hospital Universitari Germans Trias i Pujol Carretera del Canyet sin 08916 Badalona Catalonia Spain A. T. GEWIRTZ Epithelial Pathobiology Unit Department of Pathology and Laboratory Medicine Emory University School of Medicine 1364 Clifton Road, NE Atlanta, GA 30322 USA ix LIST OF PRINCIPAL CONTRIBUTORS G.R.GREENBERG Mount Sinai Hospital Room 445 600 University Avenue Toronto ON, M5G 1X5 Canada S. B. HANAUER University of Chicago Medical Centre Pritzker School of Medicine 5841 Maryland Avenue Chicago IL 60637 USA R. J. HILSDEN Department of Community Health Sciences Room 1751 3330 Hospital Drive NW Calgary AS T2N 4N1 Canada D. P. JEWELL Gastroenterology Unit The Radcliffe Infirmary Woodstock Road Oxford OX26HE UK R. S. McLEOD University of Toronto Mount Sinai Hospital 600 University Avenue, Room #449 Toronto, ON M5G 1X5 Canada x LIST OF PRINCIPAL CONTRIBUTORS F. MARTIN Honorary Professor of Medicine University of Montreal Vice-President, Scientific Affairs Axcan Pharma Inc. Canada R.G.MAUNDER Department of Psychiatry Mount Sinai Hospital 600 University Avenue Room #1401 Toronto On M5G 1X5 Canada L. MAYER The Mount Sinai Medical Center Annenberg 23-16 - Box 1089 1425 Madison Avenue New York NY 10029 USA M. J. S. MILLER Albany Medical College Department of Pediatrics 47 New Scotland Avenue Albany NY 12208 USA D.K.PODOLSKY Gastrointestinal Unit & Center for the Study of IBD Massachusetts General Hospital Harvard Medical School Boston, MA 02114 USA xi
The list of books you might like
